Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CONy 2023 | IL-6 receptor antagonists co-administered with corticosteroids to treat temporal arteritis

Temporal arteritis is a systemic inflammatory vasculitis of medium and large-sized arteries occurring most frequently in adults. Left untreated, it can result in many systemic, neurologic, and ophthalmologic complications, including irreversible vision loss. Bruno Gran, MD, PhD, FRCP, The University of Nottingham, Nottingham, UK, discusses the inclusion of IL-6 receptor antagonists, such as tocilizumab, in the treatment of temporal arteritis. Patients with temporal arteritis are standardly treated with high-dose corticosteroids. Recently, tocilizumab was proven effective in reducing the risk of relapse when co-administered with corticosteroids. However, unanswered questions about the timing of initiation, cost-effectiveness and risks require further investigations. This interview took place at the 17th World Congress on Controversies in Neurology (CONy) in Dubrovnik, Croatia.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Dr Gran has received personal compensation for consultancy from Merck, Roche, Biogen, Teva UK, and GW Pharma

Dr Gran has received unrestricted research grants from Biogen Idec, Merck, Bayer Healthcare, Teva UK, Novartis, and Genzyme

Dr Gran has received support for the attendance of clinical and research conferences from Biogen, Merck, Bayer Healthcare, Teva UK, Novartis, Genzyme, and CelGene